title: T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?
abstract: Photodynamic therapy (PDT) uses the combination of non-toxic photosensitizers and harmless light to generate reactive oxygen species that destroy tumors by a combination of direct tumor cell killing, vascular shutdown, and activation of the immune system. It has been shown in some animal models that mice that have been cured of cancer by PDT, may exhibit resistance to rechallenge. The cured mice can also possess tumor specific T-cells that recognize defined tumor antigens, destroy tumor cells in vitro, and can be adoptively transferred to protect naïve mice from cancer. However, these beneficial outcomes are the exception rather than the rule. The reasons for this lack of consistency lie in the ability of many tumors to suppress the host immune system and to actively evade immune attack. The presence of an appropriate tumor rejection antigen in the particular tumor cell line is a requisite for T-cell mediated immunity. Regulatory T-cells (CD25+, Foxp3+) are potent inhibitors of anti-tumor immunity, and their removal by low dose cyclophosphamide can potentiate the PDT-induced immune response. Treatments that stimulate dendritic cells (DC) such as CpG oligonucleotide can overcome tumor-induced DC dysfunction and improve PDT outcome. Epigenetic reversal agents can increase tumor expression of MHC class I and also simultaneously increase expression of tumor antigens. A few clinical reports have shown that anti-tumor immunity can be generated by PDT in patients, and it is hoped that these combination approaches may increase tumor cures in patients.
authors.affiliation: Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA.|Department of Dermatology, Harvard Medical School, Boston, MA, USA.
authors.forename: Florian
authors.initials: F
authors.lastname: Anzengruber
authors.affiliation: Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA.|Department of Dermatology, Harvard Medical School, Boston, MA, USA.|Department of Dermatology, Dermatooncology and Venerology, Semmelweis University School of Medicine, Budapest, 1085, Hungary.
authors.forename: Pinar
authors.initials: P
authors.lastname: Avci
authors.affiliation: Programa de Pos Graduacao Interunidades Bioengenharia - USP - Sao Carlos, Brazil.|Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA.|Department of Dermatology, Harvard Medical School, Boston, MA, USA.
authors.forename: Lucas Freitas
authors.initials: LF
authors.lastname: de Freitas
authors.affiliation: Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA.|Department of Dermatology, Harvard Medical School, Boston, MA, USA.|Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA.
authors.forename: Michael R
authors.initials: MR
authors.lastname: Hamblin
mesh_terms: D000818:Animals; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology / Q000528:radiation effects; D044127:Epigenesis, Genetic / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*; D010778:Photochemotherapy / Q000379:methods*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000528:radiation effects